Skip to main content

Market Overview

SQZ Biotechnologies Under Pressure After $60M Equity Raise At 9% Discount

  • SQZ Biotechnologies Co (NYSE: SQZprices its underwritten public offering of 3 million common shares at $20 per share. Underwriters have an option to purchase up to an additional 450,000 shares.
  • The offer price represents a discount of 9% on the last close of $22 on Thursday. The offering is expected to close on February 17.
  • BofA Securities, Evercore ISI, and Stifel are acting as joint book-running managers for the offering. BTIG is acting as the lead manager for the offering.
  • The FDA recently signed off the company's Investigational New Drug application for SQZ Activating Antigen Carriers in HPV+ tumors. The trial will investigate SQZ-AAC-HPV, a cell therapy candidate generated from red blood cells engineered with tumor-specific antigens. This trial marks the first clinical program from the company's SQZ AAC platform.
  • Price Action: SQZ stock dropped 17.7% at $18.12 in the market trading hours on the last check Friday.

Related Articles (SQZ)

View Comments and Join the Discussion!

Posted-In: Biotech News Offerings Small Cap FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at